The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma, and Patients—Part Five

Over the past several weeks, we’ve talked about how collaborations among key opinion leaders, clinical investigators and pharmaceutical and biotechnology companies benefit the companies, the KOLs or clinical investigators, and patients. The foundation of these mutually-beneficial collaborations is the objective, methodical approach to understanding KOLs’ and clinical investigators’ skills and experiences. Many methods promise to …

The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma, and Patients—Part Five Read More »